ReviewBrain pathology (Zurich, Switzerland)2018
Exploring the heterogeneity of MS lesions using positron emission tomography: a reappraisal of their contribution to disability.
Review in Brain pathology (Zurich, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Remyelination in Multiple Sclerosis: a PET-MR Longitudinal Study Investigating Individual Profiles of Myelin Repair and the Contribution of Neuroinflammation
Evaluation of the Degree of Demyelination and Remyelination in Multiple Sclerosis (MS) Detected by Brain Positron Emission Tomography With Amyloid Markers (PET-CT 18F-Florbetaben) and Comparison With MRI Findings
Who cites it
16 citing papers in PubMed, 26 citations in OpenAlex.
- Translational molecular imaging and drug development in multiple sclerosis.Theranostics · 2026Review
- The Future of PET Imaging in Multiple Sclerosis: Characterisation of Individual White Matter Lesions.Journal of clinical medicine · 2025Review
- Advanced MRI Measures of Myelin and Axon Volume Identify Repair in Multiple Sclerosis.Annals of neurology · 2024Article
- Advanced MRI Techniques: Diagnosis and Follow-Up of Multiple Sclerosis.Diagnostics (Basel, Switzerland) · 2024Review
- Microglial Positron Emission Tomography Imaging In Vivo : Positron Emission Tomography Radioligands: Utility in Research and Clinical Practice.Advances in neurobiology · 2024Review
- Association of serum neurofilament light with microglial activation in multiple sclerosis.Journal of neurology, neurosurgery, and psychiatry · 2023Article
- Neuroprotection in Cerebral Cortex Induced by the Pregnancy Hormone Estriol.Laboratory investigation; a journal of technical methods and pathology · 2023Article
- In vivo characterization of microglia and myelin relation in multiple sclerosis by combinedJournal of neurology · 2023Article
- Innate immune cells and myelin profile in multiple sclerosis: a multi-tracer PET/MR study.European journal of nuclear medicine and molecular imaging · 2022Article
- The Role of Molecular Imaging as a Marker of Remyelination and Repair in Multiple Sclerosis.International journal of molecular sciences · 2021Review
- Analyzing microglial phenotypes across neuropathologies: a practical guide.Acta neuropathologica · 2021Review
- Positron emission tomography in multiple sclerosis - straight to the target.Nature reviews. Neurology · 2021Review
- Potential Biomarkers Associated with Multiple Sclerosis Pathology.International journal of molecular sciences · 2021Review
- Structural and Clinical Correlates of a Periventricular Gradient of Neuroinflammation in Multiple Sclerosis.Neurology · 2021Article
- Promoting remyelination in multiple sclerosis.Journal of neurology · 2021Review
- Profiles of cortical inflammation in multiple sclerosis byMultiple sclerosis (Houndmills, Basingstoke, England) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The biological mechanisms driving disability worsening in multiple sclerosis (MS) are only partly understood. Monitoring changes in lesion load on MRI has a limited predictive value on the progression of clinical disability, and there is an essential need for novel imaging markers specific for the main candidate mechanisms underlying neurodegeneration which include failing myelin repair, innate immune cell activation and gray matter neuronal damage. Positron Emission Tomography (PET) is an imaging technology based on the injection of radiotracers directed against specific molecular targets, which has recently allowed the selective quantification in-vivo of the key biological mechanisms relevant to MS pathophysiology. Pilot PET studies performed in patients with all forms of MS allowed to revisit the contribution of MS lesions to disability worsening and showed that the evolution of lesions toward chronic activation, together with their remyelination profile were relevant predictors of disability worsening. PET offers the opportunity to bridge a critical gap between neuropathology and in-vivo imaging. This technique provides an original approach to disentangle some of the most relevant pathological components driving MS progression, to follow-up their temporal evolution, to investigate their clinical relevance and to evaluate novel therapeutics aimed to prevent disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.